CO2017012267A2 - Compuestos de naftiridina como inhibidores de la quinasa jak - Google Patents
Compuestos de naftiridina como inhibidores de la quinasa jakInfo
- Publication number
- CO2017012267A2 CO2017012267A2 CONC2017/0012267A CO2017012267A CO2017012267A2 CO 2017012267 A2 CO2017012267 A2 CO 2017012267A2 CO 2017012267 A CO2017012267 A CO 2017012267A CO 2017012267 A2 CO2017012267 A2 CO 2017012267A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- inhibitors
- jak kinase
- naphthyridine compounds
- provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
RESUMEN La invención provee compuestos de fórmula (I): en donde las variables se definen en la memoria descriptiva, o una sal farmacéuticamente aceptable de los mismos, que son inhibidores de quinasas JAK. La invención también provee composiciones farmacéuticas que comprende dichos compuestos, métodos para usar dichos compuestos para tratar enfermedades inflamatorias de los intestinos, y procesos e intermediarios para útiles para la preparación de dichos compuestos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562167694P | 2015-05-28 | 2015-05-28 | |
| US201662312273P | 2016-03-23 | 2016-03-23 | |
| PCT/US2016/034243 WO2016191524A1 (en) | 2015-05-28 | 2016-05-26 | Naphthyridine compounds as jak kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017012267A2 true CO2017012267A2 (es) | 2018-03-28 |
Family
ID=56118022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0012267A CO2017012267A2 (es) | 2015-05-28 | 2017-11-29 | Compuestos de naftiridina como inhibidores de la quinasa jak |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US9725470B2 (es) |
| EP (2) | EP3569604B1 (es) |
| JP (4) | JP6692836B2 (es) |
| KR (1) | KR20180011272A (es) |
| CN (2) | CN111362975B (es) |
| AU (2) | AU2016267141B2 (es) |
| BR (1) | BR112017025542A2 (es) |
| CA (1) | CA2983453A1 (es) |
| CL (1) | CL2017002994A1 (es) |
| CO (1) | CO2017012267A2 (es) |
| CY (1) | CY1122279T1 (es) |
| DK (1) | DK3303348T3 (es) |
| EA (1) | EA032953B1 (es) |
| ES (2) | ES2924698T3 (es) |
| HK (1) | HK1245771A1 (es) |
| HU (1) | HUE046130T2 (es) |
| IL (3) | IL255358B (es) |
| LT (1) | LT3303348T (es) |
| ME (1) | ME03610B (es) |
| MX (2) | MX2017015211A (es) |
| PH (1) | PH12017502050A1 (es) |
| PL (1) | PL3303348T3 (es) |
| PT (1) | PT3303348T (es) |
| RS (1) | RS59522B1 (es) |
| SA (1) | SA517390337B1 (es) |
| SG (1) | SG10201910742VA (es) |
| SI (1) | SI3303348T1 (es) |
| TW (2) | TWI746178B (es) |
| UA (1) | UA121138C2 (es) |
| WO (1) | WO2016191524A1 (es) |
| ZA (1) | ZA201707326B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016267141B2 (en) | 2015-05-28 | 2020-04-16 | Theravance Biopharma R&D Ip, Llc | Naphthyridine compounds as jak kinase inhibitors |
| PT3371185T (pt) | 2015-11-03 | 2020-12-28 | Topivert Pharma Ltd | Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase |
| WO2017077283A1 (en) | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| PT3433253T (pt) * | 2016-04-28 | 2020-04-30 | Theravance Biopharma R&D Ip Llc | Compostos de pirimidina como inibidores de jak cinases |
| AU2017377069B2 (en) | 2016-12-16 | 2020-07-23 | Janssen Pharmaceutica Nv | Small molecule inhibitors of the JAK family of kinases |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| PL3672965T3 (pl) | 2017-10-27 | 2023-01-16 | Theravance Biopharma R&D Ip, Llc | Związek pirymidynowy jako inhibitor kinazy JAK |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| WO2019246273A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| TWI740288B (zh) * | 2018-11-27 | 2021-09-21 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜芳類衍生物調節劑、其製備方法和應用 |
| CN111511738B (zh) * | 2018-11-30 | 2023-01-20 | 江苏豪森药业集团有限公司 | 杂芳类衍生物调节剂、其制备方法和应用 |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| US11155549B2 (en) | 2019-04-24 | 2021-10-26 | Theravance Biopharma R&D Ip, Llc | Ester and carbonate pyrimidine compounds as JAK kinase inhibitors |
| WO2020219640A1 (en) * | 2019-04-24 | 2020-10-29 | Theravance Biopharma R&D Ip, Llc | Pyrimidine jak inhibitors for the treatment of skin diseases |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021238908A1 (zh) * | 2020-05-25 | 2021-12-02 | 上海翰森生物医药科技有限公司 | 杂芳类衍生物的盐、晶型及其制备方法 |
| WO2022076717A1 (en) | 2020-10-09 | 2022-04-14 | Janssen Biotech, Inc. | Solvate forms of a pan-jak inhibitor |
| TW202228689A (zh) | 2020-10-09 | 2022-08-01 | 美商賽若凡斯生物製藥研發智財有限責任公司 | 泛ｊａｋ抑制劑的調配物 |
| WO2022076714A1 (en) | 2020-10-09 | 2022-04-14 | Janssen Biotech, Inc. | Solid forms of a pan-jak inhibitor |
| TW202233636A (zh) | 2020-10-09 | 2022-09-01 | 美商賽若凡斯生物製藥研發智財有限責任公司 | 製備泛ｊａｋ抑制劑之方法及相關中間化合物 |
| US20240158392A1 (en) * | 2021-02-01 | 2024-05-16 | Janssen Biotech, Inc. | Small molecule inhibitors of salt inducible kinases |
| WO2022241188A1 (en) | 2021-05-14 | 2022-11-17 | Theravance Biopharma R&D Ip, Llc | Enantioselective synthesis of aminotropane compound |
| WO2023011359A1 (zh) * | 2021-08-05 | 2023-02-09 | 南京明德新药研发有限公司 | 桥环类化合物及其应用 |
| WO2023102800A1 (en) | 2021-12-09 | 2023-06-15 | Theravance Biopharma R&D Ip, Llc | Synthesis of 5, 7-dichloro-1, 6-naphthyridine |
| WO2023202706A1 (zh) * | 2022-04-21 | 2023-10-26 | 南京明德新药研发有限公司 | 硒杂环类化合物的盐型和晶型及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| MXPA03005610A (es) | 2000-12-21 | 2003-10-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de la proteina cinasa. |
| EP1595881A1 (en) * | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| CA2588220A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Products Inc. | Heteroaromatic derivatives useful as anticancer agents |
| US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| EP2142550A1 (en) * | 2007-04-02 | 2010-01-13 | Palau Pharma, S.A. | Pyrrolopyrimidine derivatives as jak3 inhibitors |
| US20110269740A1 (en) * | 2008-07-02 | 2011-11-03 | Ambit Biosciences Corporation | Jak kinase modulating compounds and methods of use thereof |
| EP2324022A1 (de) * | 2008-08-05 | 2011-05-25 | Boehringer Ingelheim International GmbH | Substituierte naphthyridine und ihre verwendung als arzneimittel |
| RU2011116928A (ru) | 2008-09-30 | 2012-11-20 | Астразенека Аб (Se) | Гетероциклические ингибиторы jак киназы |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| WO2012022045A1 (en) * | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| CN105367555B (zh) | 2014-08-07 | 2019-06-25 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| AU2016267141B2 (en) | 2015-05-28 | 2020-04-16 | Theravance Biopharma R&D Ip, Llc | Naphthyridine compounds as jak kinase inhibitors |
| PT3433253T (pt) | 2016-04-28 | 2020-04-30 | Theravance Biopharma R&D Ip Llc | Compostos de pirimidina como inibidores de jak cinases |
-
2016
- 2016-05-26 AU AU2016267141A patent/AU2016267141B2/en not_active Ceased
- 2016-05-26 CN CN202010325911.7A patent/CN111362975B/zh active Active
- 2016-05-26 PL PL16728495T patent/PL3303348T3/pl unknown
- 2016-05-26 CN CN201680029912.9A patent/CN107667108B/zh active Active
- 2016-05-26 DK DK16728495T patent/DK3303348T3/da active
- 2016-05-26 BR BR112017025542-1A patent/BR112017025542A2/pt active Search and Examination
- 2016-05-26 HU HUE16728495A patent/HUE046130T2/hu unknown
- 2016-05-26 EP EP19182836.7A patent/EP3569604B1/en active Active
- 2016-05-26 ES ES19182836T patent/ES2924698T3/es active Active
- 2016-05-26 ES ES16728495T patent/ES2753159T3/es active Active
- 2016-05-26 MX MX2017015211A patent/MX2017015211A/es unknown
- 2016-05-26 PT PT167284959T patent/PT3303348T/pt unknown
- 2016-05-26 WO PCT/US2016/034243 patent/WO2016191524A1/en active Application Filing
- 2016-05-26 MX MX2020011774A patent/MX2020011774A/es unknown
- 2016-05-26 RS RS20191390A patent/RS59522B1/sr unknown
- 2016-05-26 KR KR1020177037794A patent/KR20180011272A/ko not_active Application Discontinuation
- 2016-05-26 SI SI201630490T patent/SI3303348T1/sl unknown
- 2016-05-26 CA CA2983453A patent/CA2983453A1/en not_active Abandoned
- 2016-05-26 ME MEP-2019-289A patent/ME03610B/me unknown
- 2016-05-26 UA UAA201712873A patent/UA121138C2/uk unknown
- 2016-05-26 SG SG10201910742VA patent/SG10201910742VA/en unknown
- 2016-05-26 LT LT16728495T patent/LT3303348T/lt unknown
- 2016-05-26 EA EA201792619A patent/EA032953B1/ru unknown
- 2016-05-26 US US15/165,126 patent/US9725470B2/en active Active
- 2016-05-26 JP JP2017561259A patent/JP6692836B2/ja active Active
- 2016-05-26 EP EP16728495.9A patent/EP3303348B1/en active Active
- 2016-05-27 TW TW109132390A patent/TWI746178B/zh not_active IP Right Cessation
- 2016-05-27 TW TW105116751A patent/TWI704152B/zh not_active IP Right Cessation
-
2017
- 2017-06-23 US US15/631,220 patent/US10072026B2/en active Active
- 2017-10-27 ZA ZA2017/07326A patent/ZA201707326B/en unknown
- 2017-10-31 IL IL255358A patent/IL255358B/en active IP Right Grant
- 2017-11-09 PH PH12017502050A patent/PH12017502050A1/en unknown
- 2017-11-14 SA SA517390337A patent/SA517390337B1/ar unknown
- 2017-11-27 CL CL2017002994A patent/CL2017002994A1/es unknown
- 2017-11-29 CO CONC2017/0012267A patent/CO2017012267A2/es unknown
-
2018
- 2018-04-18 HK HK18105049.0A patent/HK1245771A1/zh unknown
- 2018-08-06 US US16/055,386 patent/US10494382B2/en active Active
-
2019
- 2019-10-11 US US16/599,434 patent/US10947254B2/en active Active
- 2019-11-06 CY CY20191101165T patent/CY1122279T1/el unknown
-
2020
- 2020-01-15 IL IL272057A patent/IL272057B/en active IP Right Grant
- 2020-03-19 JP JP2020049467A patent/JP6850922B2/ja active Active
- 2020-03-27 AU AU2020202181A patent/AU2020202181B2/en not_active Ceased
- 2020-08-12 IL IL276677A patent/IL276677B/en active IP Right Grant
- 2020-09-16 JP JP2020155460A patent/JP6942853B2/ja active Active
-
2021
- 2021-02-10 US US17/248,832 patent/US11780852B2/en active Active
- 2021-03-22 JP JP2021047526A patent/JP2021098757A/ja not_active Withdrawn
-
2023
- 2023-09-05 US US18/242,434 patent/US20240132520A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017012267A2 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
| CO2018005640A2 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
| CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CO2018004124A2 (es) | Compuestos heterocíclicos | |
| CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
| CO2020001469A2 (es) | Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CL2017002650A1 (es) | Compuestos novedosos | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
| CL2017000712A1 (es) | Pirimidinonas como inhibidores del factor xia | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| CU24496B1 (es) | Derivados de pirazol-3-il-amina sustituidos como inhibidores de cdk | |
| EA201791576A1 (ru) | Ингибитор jak | |
| EA201592199A1 (ru) | Производные бипиразола в качестве ингибиторов jak | |
| MY197440A (en) | Heteroamatic compounds as btk inhibitors | |
| UY35972A (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| PH12016501462A1 (en) | Neprilysin inhibitors | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| UY36228A (es) | Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen |